MC2 Therapeutics to Present at Upcoming Conferences

*MC2 Therapeutics to Present at Upcoming Conferences*

*Copenhagen, February 26*^*th**, 2024 –* MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today that its leadership will attend and present at the following industry conferences:

· *17*^*th** Annual European Life Sciences CEO Forum, Zürich* February 28^th-29^th (presentation at 3:20pm CET, February 28^th - Track C - Room Panorama C)
· *TD Cowen Annual Health Care Conference, Boston* March 4^th-6^th (hosting 1:1 meetings with investors on March 4^th at the event)
· *American Academy of Dermatology Annual Meeting, San Diego* March 8^th-12^th
· *Kempen Life Science Conference, Amsterdam* April 16^th-17^th (presentation on April 16^th)
· *Bio€quity Europe, San Sebastian* May 12^th-14^th (presentation time and location to be announced)
Any webcasts will be available on MC2’s website following the presentations. Please contact us if you would like to arrange a meeting.

*About MC2 Therapeutics*
MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking.

Its pipeline includes two first-in-class drug candidates both in Phase 2 clinical development, with novel modes of action and blockbuster potential in multiple indications (“I&I pipeline in a product”):

· *MC2-32:* an oral HSP90 inhibitor with unique tissue specific targeting and a new MOA that modulates multiple pro-inflammatory pathways and relevant immune responses.· *MC2-25*: an iso-cyanate scavenger addressing carbamylation of proteins and amino acids in the skin by iso-cyanate, a dissociation product of urea.
For additional information on MC2 Therapeutics, please visit *www.mc2therapeutics.com*.

*Contacts:*
Lonni Goltermann, +45 2018 1111, *investor@mc2therapeutics.com*

*Media: ICR Consilium*
Amber Fennell, +44 20 3709 5700, *MC2@consilium-comms.com*